Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Nikolaos Zacharakis(National Institutes of Health), Harshini Chinnasamy(National Institutes of Health), Mary A. Black(National Institutes of Health), Hui Xu(National Institutes of Health), Yong‐Chen Lu(National Institutes of Health), Zhili Zheng(National Institutes of Health), Anna Pasetto(National Institutes of Health), Michelle M. Langhan(National Institutes of Health), Thomas E. Shelton(National Institutes of Health), Todd D. Prickett(National Institutes of Health), Jared J. Gartner(National Institutes of Health), Lee Jia(National Institutes of Health), Katarzyna Trebska-McGowan(Virginia Commonwealth University), Robert Somerville(National Institutes of Health), Paul F. Robbins(National Institutes of Health), Steven A. Rosenberg(National Institutes of Health), Stephanie L. Goff(National Institutes of Health), Steven A. Feldman(National Institutes of Health)
Nature Medicine
May 29, 2018
10.1038/s41591-018-0040-8
Cited by 776

Abstract

Related Papers

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al.|Breast Care|2016|30.9k
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al.|Cancer Discovery|2012|18.3k
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al.|Oncology|2013|13.2k
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network|Nature|2012|12.4k
Signatures of mutational processes in human cancer
Australian Pancreatic Cancer Genome Initiative, Ludmil B. Alexandrov, ICGC PedBrain et al.|Nature|2013|10.1k